TD Cowen analyst Ritu Baral maintains $Neurogene (NGNE.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 52.1% and a total average return of 17.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
Preliminary data from the Phase 1/2 study of NGN-401 suggests a distinct efficacy signal, demonstrating what appears to be genuine clinical improvements in 4 pediatric patients with Rett syndrome. The primary concern may revolve around the serious adverse event (SAE) observed at the higher dosage of NGN-401 and the associated risk profile for the treatment program. Although details about this SAE are limited due to recent awareness, it is noted that the observed efficacy of NGN-401 has been at the lower dose, which to date seems to have a relatively safe profile.
The validation of NGN-401 in Rett syndrome through the company's Phase 1/2 readout highlighted unprecedented and potentially approvable efficacy, along with favorable safety at a low dosage. However, the analyst notes that investor attention was drawn to the uncertainty surrounding a serious adverse event that occurred in the high dosage cohort.
The firm expressed optimism regarding Neurogene's stock following the company's announcement of initial interim clinical data for its gene therapy NGN-401 in Rett syndrome. The analyst believes that the efficacy data is more likely than not sufficient to support approval.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Ritu Baral維持$Neurogene (NGNE.US)$買入評級。
根據TipRanks數據顯示，該分析師近一年總勝率為52.1%，總平均回報率為17.2%。
此外，綜合報道，$Neurogene (NGNE.US)$近期主要分析師觀點如下：
NGN-401 1/2 期研究的初步數據表明存在明顯的療效信號，這表明 4 名雷特綜合徵兒科患者的臨床改善似乎是真實的。主要問題可能圍繞在較高劑量的 NGN-401 時觀察到的嚴重不良事件 (SAE) 以及治療計劃的相關風險概況展開。儘管由於最近的認識，有關該SAE的細節有限，但值得注意的是，NGN-401 的觀察到的療效是在較低的劑量下，迄今爲止，這種劑量似乎相對安全。
通過公司的第 1/2 期讀數對 NGN-401 在雷特綜合徵中的驗證凸顯了前所未有且可能獲得批准的療效，以及低劑量下良好的安全性。但是，分析師指出，圍繞高劑量人群中發生的嚴重不良事件的不確定性，吸引了投資者的注意力。
在Neurogene公佈了其治療雷特綜合徵的基因療法 NGN-401 的初步中期臨床數據後，該公司對該公司的股票表示樂觀。分析師認爲，療效數據很可能不足以支持批准。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
